She had been fit and well with no serious childhood illnesses and no family history of any significant diseases. She had participated in sport and enjoyed dance. Ruth woke up one morning with a high temperature, a sore throat and muscle pains. Both she and her GP, whom she consulted, considered that she had a bout of flu.
U.S. Food and Drug Administration
(mh=09RYZc9G84XJ1Yny)1.jpg)
(mh=_XKMrij_cpnzN_Jj)11.jpg)
(mh=0eI1jrGEoG__08hp)3.jpg)
Adult-Onset Still's Disease: Still a Serious Health Problem (a Case Report and Literature Review)
Central Avenue No. We report an interesting case of a year-old African-American male who presented with one-month duration of FUO along with skin rash, sore throat, and arthralgia. After extensive workup, potential differential diagnoses were ruled out and the patient was diagnosed with AOSD based on the Yamaguchi criteria. The case history, incidence, pathogenesis, clinical manifestations, differential diagnoses, diagnostic workup, treatment modalities, and prognosis of AOSD are discussed in this case report.
Treatment of adult-onset still's disease: up to date
As the name suggests, it can only be diagnosed in adults. Systemic JIA is only diagnosed in children. The immune system protects us from infection and other threats to the body, but in AOSD it attacks your own body by mistake. AOSD can cause pain and stiffness in your joints, as well as inflammation in other areas of your body. Some people may not have all these symptoms at once, which can make it difficult to diagnose the condition.
Due to rarity of disease, treatment of AOSD is not based on controlled study, but on case based experiences. Areas covered: Recently, the application of anti-cytokine therapy based on pathophysiology has resulted in significant progress in the treatment of AOSD. Here, we review current knowledge of the pathogenesis, disease progression, currently available biomarkers of disease activity, standard therapeutic agents, utility of biologic agents, future perspectives for treatment and treatment of macrophage activation syndrome. Expert commentary: Accumulated clinical data suggest that chronic disease can be classified into two subsets: dominant systemic disease, and the arthritis subgroup. IL-1 inhibitors may be more efficient for systemic manifestations and IL-6 inhibitor for both joint involvement and systemic manifestations.
